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Objective/purpose
Fenretinide [N-4-hydroxyphenyl, 4HPR] is a synthetic
retinoid derived from vitamin A with pro-apoptotic and
anti-inflammatory properties. Studies have shown that
at high concentrations fenretinide is an effective anti-
neoplastic agent, regulating cell growth and differentia-
tion. We have recently demonstrated that fenretinide, at
doses 5-10× lower than for cancer treatment, has pro-
tective effect against bacterial infection[1] and osteo-
porosis[2] in Cftr-knockout mice. The effect of
fenretinide as a potential treatment for allergic asthma
induced inflammation has not been evaluated in asth-
matics. The goal of this study was to determine if, by
normalizing inflammatory mediators, fenretinide would
be able to alleviate the symptoms associated with aller-
gic asthma.
Methods
Hyperresponsive to methacholine, mice of A/J strain
were sensitized weekly using ovalbumin (OVA) for
three consecutive weeks, then age-matched and sepa-
rated into two study groups and two control groups.
For a period of 4 weeks, the study groups were orally
treated with fenretinide while the controls were treated
with the drug vehicle. During the last week of treat-
ment, the control and study groups were split into two
additional groups and underwent allergen challenges
for three consecutive days, with either an OVA solu-
tion or PBS. Forty-eight hours after the third challenge,
resistance of the respiratory system of the mice in
response to methacholine was measured using a Buxco
plethysmograph. Total IgE in plasma was measured by
ELISA. Lung histopathology was observed using H&E
and PAS stains.
Findings
Vehicle treated OVA challenged mice exhibited high
values of airway resistance, plasma IgE concentration,
and immune cell infiltration into the airways compared
to PBS challenged animals. Interestingly, fenretinide
treated OVA challenged mice had a statistically lower
respiratory resistance. In addition, fenretinide treatment
abrogated the recruitment of eosinophils to the region
surrounding the blood vessels and airways. Similarly,
after drug treatment a decrease in goblet cell hyperplasia
was also observed through histopathology. However, no
difference was observed in the level of plasma IgE
between the control and study groups.
Deliverables
Fenretinide has been demonstrated to have great poten-
tial as a therapeutic agent. Our findings provide a novel
approach to treat allergen-induced asthma and will help
us in pursuing these studies towards the use of this
drug for patients suffering from allergic asthma.
Relevance
The data presented herein will facilitate the develop-
ment of fenretinide as a therapeutic compound in the
treatment of allergic asthma and provide the foundation
for the identification of drug targets for the development
of effective future drugs.
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